title: Partial- and full-mouth scaling and root planing in type 2 diabetic subjects: a 12-mo follow-up of clinical parameters and levels of cytokines and osteoclastogenesis-related factors.
abstract: OBJECTIVE
  The aim of this study was to evaluate the effects of full-mouth scaling and root planing (FMSRP) and partial-mouth scaling and root planing (PMSRP), up to 12 mo after treatment, on clinical parameters, and levels of cytokines and osteoclastogenesis-related factors in type 2 diabetic subjects with chronic periodontitis.
  
  
  METHODS
  Thirty-four subjects received FMSRP (n = 17) or PMSRP (n = 17) within 24 h or in multiple sessions, respectively. Clinical parameters and local levels of tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin (IL)-17, IL-23, IL-4, receptor activator of NF-β ligand and osteoprotegerin were assessed at baseline, and 3, 6 and 12 mo after therapies.
  
  
  RESULTS
  Clinical parameters improved after both therapies (p < 0.05), and no between-group differences were observed at any time-point (p > 0.05). Overall, there were no considerable differences in the local levels of the biomarkers studied between groups (p > 0.05). The IL-23 concentration and total amount of IFN-γ increased in the FMSRP group and decreased in the PMSRP group from baseline to 3 mo and from baseline to 6 mo, respectively (p < 0.05).
  
  
  CONCLUSIONS
  Both PMSRP and FMSRP promoted benefits in clinical parameters and showed a similar modulation of cytokines and osteoclastogenesis-related factors at 12 mo in type 2 diabetic subjects.
authors.affiliation: Department of Periodontology, Dental Research Division, Guarulhos University, Guarulhos, São Paulo, São Paulo, Brazil.
authors.forename: V R
authors.initials: VR
authors.lastname: Santos
authors.forename: F V
authors.initials: FV
authors.lastname: Ribeiro
authors.forename: J A
authors.initials: JA
authors.lastname: Lima
authors.forename: T S
authors.initials: TS
authors.lastname: Miranda
authors.forename: M
authors.initials: M
authors.lastname: Feres
authors.forename: M F
authors.initials: MF
authors.lastname: Bastos
authors.forename: P M
authors.initials: PM
authors.lastname: Duarte
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D055113:Chronic Periodontitis / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000032:analysis*; D012534:Dental Scaling / Q000379:methods*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D005883:Gingival Crevicular Fluid / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis; D020381:Interleukin-17 / Q000032:analysis; D053759:Interleukin-23 / Q000032:analysis; D015847:Interleukin-4 / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010010:Osteoclasts / Q000502:physiology*; D053244:Osteoprotegerin / Q000032:analysis; D017622:Periodontal Attachment Loss / Q000628:therapy; D010514:Periodontal Pocket / Q000628:therapy; D011446:Prospective Studies; D053245:RANK Ligand / Q000032:analysis; D016745:Root Planing / Q000379:methods*; D016037:Single-Blind Method; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
chemical_list: D015415:Biomarkers; D016207:Cytokines; D020381:Interleukin-17; D053759:Interleukin-23; D053244:Osteoprotegerin; D053245:RANK Ligand; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D007371:Interferon-gamma